Grufity logo
Grufity logo
NXL

NXL - Nexalin Technology Inc Stock Price, Fair Value and News

$5.00+0.01 (+0.20%)
Delayed as of 15 Sep 2026, 11:32 am ET

NXL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NXL Price Action

Last 7 days

-2.2%

Last 30 days

1314.3%

Last 90 days

1169.2%

Trailing 12 Months

462.5%

NXL RSI Chart

NXL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NXL Valuation

Market Cap

110.0M

Price/Earnings (Trailing)

-12.23

Price/Sales (Trailing)

506.37

EV/EBITDA

-12.29

Price/Free Cashflow

-17.94

NXL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

NXL Fundamentals

NXL Revenue

Revenue (TTM)

217.2K

Rev. Growth (Yr)

-82.77%

Rev. Growth (Qtr)

-18.66%

NXL Earnings

Earnings (TTM)

-9.0M

Earnings Growth (Yr)

-41.63%

Earnings Growth (Qtr)

-6.79%

NXL Profitability

Operating Margin

86.16%

EBT Margin

-4139.38%

Return on Equity

-591.6%

Return on Assets

-299.21%

Free Cashflow Yield

-5.57%

NXL Investor Care

Shares Dilution (1Y)

40.20%

Diluted EPS (TTM)

-11.06

Revenue & Growth

How Nexalin Technology Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026275.6K217.2K--
2025131.1K174.8K156.9K301.6K
2024158.9K150.2K162.1K168.7K
20231.0M716.1K413.4K110.7K
2022438.4K732.7K1.0M1.3M
2021---144.1K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Nexalin Technology Inc

NXL
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. In addition, it designs and develops Generation 2 and Generation 3, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, Alzheimer's disease, and dementia. The company is based in Houston, Texas.
 CEO
 WEBSITEnexalin.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES6

Nexalin Technology Inc Frequently Asked Questions

NXL is the stock ticker symbol of Nexalin Technology Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Sep 14 2026, market cap of Nexalin Technology Inc is 109.96 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Sep 14 2026, NXL's PE ratio (Price to Earnings) is -12.23 and Price to Sales (PS) ratio is 506.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NXL PE ratio will change depending on the future growth rate expectations of investors.